Home > Oncology > WCLC 2019 > Phase 3 Trial Updates > First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression

First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression

Presented By
Dr Martin Reck, Lung Clinic Grosshansdorf, Germany
Conference
WCLC 2019
Trial
KEYNOTE-024
It has been shown after a follow-up of more than 3 years that first-line pembrolizumab monotherapy provides durable long-term overall survival (OS) compared to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). This OS benefit was observed despite 65% of patients assigned to chemotherapy crossing over to pembrolizumab. Furthermore, pembrolizumab had a manageable long-term safety profile. Dr Martin Reck (Lung Clinic Grosshansdorf, Germany) presented data on 3-year survival from the KEYNOTE-024. Patients with advanced NSCLC who had programmed death-ligand 1 (PD-L1) ≥50% and who had no targetable epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) alterations had been randomised to pembrolizumab or platinum-based chemotherapy. Earlier results had already shown that first-line pembrolizumab significantly improved progression-free survival (PFS) as well as OS compared with chemotherapy [1]. For this longer fol...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on